A look back at an energetic H1 and what to expect next
The biopharma sector has always been seen as a safe harbor in times of economic uncertainty — the need for medical innovations to improve human health persists equally through bull and bear markets. In the COVID-19 pandemic, capital has flowed into the industry not just because of its counter-cyclical nature but also in recognition of its role in developing vaccines and treatments that offer hope against the disease.
The result has been an extraordinary windfall of investment in the sector — one that only accelerated through the first half of 2021. In this report, we review the deals that took place in H1 2021 and how they will impact the second half of the year.